Makes sense.
It's a bit hard to draw conclusions regarding PFS from the data they've given us but obviously they've got a bit more data than us and know it's positive. As someone else mentioned too - only 3 or 4 of the 14 were on the 400mg dose that was ultimately chosen for 2a.
Market still staying away from this one until capital sorted out. I'm still expecting a cap raise reasonably soon.
Ann: Update on ACCENT Trial in Pancreatic Cancer, page-13
Add ATX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.8¢ |
Change
-0.005(6.85%) |
Mkt cap ! $18.46M | |||
| Open | High | Low | Value | Volume |
| 7.2¢ | 7.3¢ | 6.8¢ | $10.78K | 154.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 16129 | 6.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.0¢ | 21334 | 1 |
View Market Depth
| Last trade - 15.59pm 13/06/2024 (20 minute delay) ? |
|
|||||
|
Last
6.8¢ |
Change
-0.005 ( 5.56 %) |
||||
| Open | High | Low | Volume | ||
| 7.1¢ | 7.1¢ | 6.8¢ | 10032 | ||
| Last updated 15.59pm 13/06/2024 ? | |||||
| ATX (ASX) Chart |